U.S., European Biosimilar Approval Activity in 2017
U.S. Biosimilar Launches Accelerate with Five Launches in Q4 2019 and early 2020 | Biosimilars Law Bulletin
761072Orig1s000
Remicade® (infliximab): 20 years of contributions to science and m | BTT
FDA Approves First Subcutaneous Infliximab for IBD
AVSOLA®(infliximab-axxq)'s Totality of Evidence
g30513mm01i001.jpg
FDA Approves Remicade Biosimilar
Fuld & Company | Biosimilar Infliximab - What's All the Excitement About? - Fuld & Co
Remicade (infliximab) FDA Approval History - Drugs.com
REMICADE® (infliximab) Overview | Janssen CarePath for Healthcare Professionals
Remicade (infliximab): Uses, Side Effects, Dosage & Reviews
Ask the Expert—Are biosimilars as effective as their biologic counterparts?
The US Biosimilar Market Where Is It Today And Where Is It Going
Samsung Bioepis and Merck Launch Renflexis® in the U.S. | Biosimilars Law Bulletin
AVSOLA®(infliximab-axxq)'s Totality of Evidence
Pivotal Clinical Trials
Biosimilar strategy for infliximab by MedDrive™ includes the reference drug - Prime Therapeutics LLC
Celltrion Scores FDA Approval of SC Infliximab: Will Use of the IV Formulation Be Affected? | BR&R
Biosimilar medicine fact sheet – infliximab | Australian Government Department of Health and Aged Care
These highlights do not include all the information needed to use REMICADE® safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab) for injection, for intravenous use Initial U.S. Approval: 1998
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
J&J braces for biosim attack after losing last-ditch Remicade patent fight | Fierce Pharma
